XNAS · Healthcare · Biotechnology
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -1.65 | -1.67 | -1.21% | $19.4M | ❌ Miss | -1.22% | -2.96% | — |
| 2026-02-24 | Q4 2025 | -1.41 | -1.50 | -6.38% | $17.8M | ❌ Miss | -0.87% | -13.38% | -9.45% |
| 2025-11-05 |
| Q3 2025 |
| -1.58 |
| -1.54 |
| +2.53% |
| $1.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -1.35 | -1.12 | +17.04% | $66.8M | ✅ Beat | — | — | — |
| 2025-05-06 | Q1 2025 | -1.36 | -1.36 | +0.00% | $1.6M | ➖ Inline | — | — | — |
| 2025-02-27 | Q4 2024 | -1.17 | -1.26 | -7.69% | $16.9M | ❌ Miss | — | — | — |
| 2024-11-06 | Q3 2024 | -1.26 | -1.36 | -7.94% | $463,000 | ❌ Miss | — | — | — |
| 2024-08-08 | Q2 2024 | -1.06 | -1.31 | -23.58% | $249,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.